The d18:1 S1P and 18:1 LPA are the most abundant endogenous lipid agonists for S1P1 and LPA1, respectively, while Siponimod represents a synthetic compound specifically targeting S1P1 and S1P5 among the five S1P receptor subtypes, and has recently been approved to treat MS. This evidence concerns the gene S1PR5 and myeloid sarcoma.